NUTRA PHARMA CORP

Overview

Compare with Glucose Health, Inc., China Foods Holdings Ltd. or Adia Med, Inc., or pick any stock.

• TickerNPHC on OTC¹
• IndustryMedicinal Chemicals & Botanical Products¹
• HeadquartersBoca Raton, Florida¹
• Incorporated inCA²
• Business address6400 Park Of Commerce Blvd, Suite 1B, Boca Raton, Fl 33487²
• Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Pharma is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain.³ From its latest annual report

Corporate structure

NUTRA PHARMA CORP sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NUTRA PHARMA CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Inventory

Properties, in its own words

We leased an aggregate of 5,500 square feet of office, laboratory, and warehouse space at 1537 NW 65th Avenue, Plantation, Florida. The lease with Shelter Developers of America (“Shelter”) was renewed through December 31, 2025, with no further renewal. The lease called for monthly payments of approximately $8,500, which included base rent, common area expenses, real estate taxes and insurance. In September of 2023, we moved our operations to 6400 Park of Commerce Blvd, Suite 1B, Boca Raton, Florida. We share 18,504 square feet with Avini Health, a private dietary supplement company. We have use of a laboratory, conference room, production suites and 3 offices. Avini Health grants us the use of the facilities as part of our contract manufacturing agreements without further payments.

Item 2 of the 10-K filed May 20, 2026.³

Leadership

Who has led NUTRA PHARMA CORP, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRik J. Deitsch Apr 1, 2008 to Jan 14, 2022¹²
• ChairMichael Doherty May 2, 2006 to May 2, 2006¹³
• PresidentHarold Henry Rumph Mar 21, 2014 to Mar 21, 2014¹⁴
• PresidentRik J. Deitsch Apr 1, 2008 to Jan 14, 2022¹²
• Chief financial officerRik J. Deitsch Apr 1, 2008 to Apr 1, 2008¹²

Former names

• CYBER VITAMIN COMOct 3, 2000 to Feb 28, 2002²

Timeline

1. Sep 2, 20268-K Change in control²²
2. Sep 3, 20258-K Change of auditor²³
3. Mar 22, 20248-K Executive or director change; Regulation FD disclosure; Other events²⁴
4. Aug 4, 20228-K Change of auditor²⁵
5. Apr 1, 2008New chief executive Rik J. Deitsch becomes CEO¹²

Filings

36 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 4 major events, 3 insider forms, 2 large holders, 7 other. The latest 20:

1. Sep 2, 20268-K EDGAR
2. Sep 1, 2026SCHEDULE 13D EDGAR
3. Sep 1, 20263 EDGAR
4. Sep 1, 20264 EDGAR
5. Aug 19, 202610-Q EDGAR
6. Aug 14, 2026NT 10-Q EDGAR
7. May 29, 202610-Q EDGAR
8. May 20, 202610-K EDGAR
9. Apr 6, 202610-Q EDGAR
10. Mar 25, 202610-Q EDGAR
11. Mar 11, 202610-Q EDGAR
12. Feb 17, 202610-K EDGAR
13. Jan 2, 202610-Q EDGAR
14. Dec 23, 202510-Q EDGAR
15. Dec 17, 202510-Q EDGAR
16. Nov 24, 202510-K EDGAR
17. Oct 28, 202510-Q EDGAR
18. Oct 23, 202510-Q EDGAR
19. Oct 16, 202510-Q EDGAR
20. Sep 3, 202510-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Pure Raw Supplies, LLCSCHEDULE 13D, 1 filing Sep 1, 2026²⁶
• Rik J. DeitschSC 13D/A, 1 filing Jan 14, 2022²⁷

SEC filer profile

How NUTRA PHARMA CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARNUTRA PHARMA CORP¹
• CIK0001119643
• Employer ID (EIN)91-2021600³
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inCalifornia³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2833 Medicinal Chemicals & Botanical Products¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address6400 Park Of Commerce Blvd, Suite 1B, Boca Raton, FL 33487¹
• Phone(954) 509-0911¹
• Shares outstanding7,159,727,214 as of Aug 19, 2026¹¹
• Public float$702.7K as of Jun 30, 2025³
• AuditorAstra Audit & Advisory, Tampa, Florida PCAOB ID 6920³
• On EDGAR sinceAug 24, 2000¹
• Filings349 in all: 10-Q (63), 8-K (51), NT 10-Q (38), 4 (28), 10-K (19), NT 10-K (18), 3 (17), 10QSB (14)¹
  All 37 form types

  5 (11), 10-Q/A (9), 8-K/A (9), SC 13D (9), SB-2/A (7), 10KSB (6), CORRESP (6), UPLOAD (6), 10QSB/A (5), SC 13D/A (5), 10KSB/A (4), 10-K/A (3), DEF 14A (2), DEF 14C (2), PRE 14C (2), S-8 (2), 3/A (1), 4/A (1), 8-A12G (1), DEFS14A (1), EFFECT (1), NTN 10Q (1), PRE 14A (1), S-1 (1), S-1/A (1), SB-2 (1), SC 13G (1), SC 13G/A (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (10-K) May 20, 2026
  Quarterly report (10-Q) Aug 19, 2026
  Proxy statement (DEF 14A) Mar 17, 2015
  Latest 8-K (8-K) Sep 2, 2026

Risk factors and legal proceedings

The risks NUTRA PHARMA CORP names in Item 1A of its 10-K filed May 20, 2026: 24 risks under these headings, as written.³

• We have identified material weaknesses in our internal control over financial reporting, which could adversely affect our financial condition, access to capital, and the market price of our common stock
• Our ability to continue as a going concern is in doubt absent obtaining adequate new debt or equity financing and achieving sufficient sales levels.
• We have a limited revenue producing history with significant losses and expect losses to continue for the foreseeable future.
• We will require additional financing to sustain our operations and without it will be unable to continue operations.
• We have a history of failed distributors, which has negatively affected our revenues and may continue to do so if we fail to locate a successful distributor.
• If we cannot sell a sufficient volume of our products, we will be unable to continue in business.
• We have a limited history of generating revenues on which to evaluate our potential for future success and to determine if we will be able to execute our business plan; accordingly, it is difficult to evaluate our future prospects and the risk of success or failure of our business.
• Our growth strategy reflected in our business plan may be unachievable or may not result in profitability.
• If we cannot manage our growth effectively, we may not become profitable.
• If we are unable to protect our proprietary technology, our business could be harmed.
• We are subject to substantial FDA regulations pertaining to Nyloxin and Pet Pain-Away, which may increase our costs or otherwise adversely affect our operations.
• The inability to provide scientific proof for product claims may adversely affect our sales.

Legal proceedings

Marc Weller v. Nutra Pharma Corporation, Case No. CACE-24-018346

In January 2026, the Company entered into a settlement agreement with Marc Weller resolving litigation in Broward County, Florida. Pursuant to the settlement, the Company agreed to cancel and extinguish outstanding notes with an aggregate carrying value of approximately $175,000 in exchange for $20,000 in cash (payable in installments through April 2026) and the issuance of 60 million shares of common stock.

CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150

On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. The Company filed its Answer and Affirmative Defenses on November 1, 2018, and asserted counterclaims against the plaintiff and certain related parties. Mediation was held on June 21, 2019 but did not result in a resolution at that time. The dispute remained ongoing until it was resolved through settlement in May 2025.

The opening of Item 3, Legal Proceedings.³